loading
전일 마감가:
$59.73
열려 있는:
$59.98
하루 거래량:
1.25M
Relative Volume:
0.63
시가총액:
$12.10B
수익:
$4.08B
순이익/손실:
$32.48M
주가수익비율:
421.29
EPS:
0.14
순현금흐름:
$16.80M
1주 성능:
-5.68%
1개월 성능:
+0.20%
6개월 성능:
-29.26%
1년 성능:
+10.24%
1일 변동 폭
Value
$58.94
$60.48
1주일 범위
Value
$57.77
$62.80
52주 변동 폭
Value
$52.81
$83.95

인사이트 코퍼레이션 Stock (INCY) Company Profile

Name
명칭
Incyte Corp
Name
전화
(302) 498-6700
Name
주소
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Name
직원
2,617
Name
트위터
@Incyte
Name
다음 수익 날짜
2025-02-10
Name
최신 SEC 제출 서류
Name
INCY's Discussions on Twitter

INCY을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
INCY
Incyte Corp
58.98 12.10B 4.08B 32.48M 16.80M 0.14
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
424.99 128.84B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
527.78 65.38B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ARGX
Argen X Se Adr
549.65 39.67B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.15 33.82B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
231.99 27.60B 3.81B -644.79M -669.77M -6.24

인사이트 코퍼레이션 Stock (INCY) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-18 다운그레이드 Guggenheim Buy → Neutral
2025-03-18 다운그레이드 William Blair Outperform → Mkt Perform
2024-12-17 개시 UBS Neutral
2024-10-29 업그레이드 BofA Securities Neutral → Buy
2024-10-01 개시 Wolfe Research Outperform
2024-09-18 다운그레이드 Truist Buy → Hold
2024-07-02 다운그레이드 BMO Capital Markets Market Perform → Underperform
2024-05-23 개시 Deutsche Bank Hold
2024-04-23 개시 Cantor Fitzgerald Neutral
2024-02-23 개시 Jefferies Buy
2024-02-14 다운그레이드 JMP Securities Mkt Outperform → Mkt Perform
2023-12-13 업그레이드 Leerink Partners Market Perform → Outperform
2023-12-04 업그레이드 Guggenheim Neutral → Buy
2023-11-21 다운그레이드 Goldman Buy → Neutral
2023-07-25 개시 Citigroup Buy
2023-05-04 다운그레이드 BofA Securities Buy → Neutral
2023-04-10 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2023-03-24 업그레이드 SVB Securities Underperform → Market Perform
2023-01-31 개시 Piper Sandler Overweight
2022-08-03 다운그레이드 Evercore ISI Outperform → In-line
2022-08-03 다운그레이드 Guggenheim Buy → Neutral
2022-07-28 개시 Wells Fargo Equal Weight
2022-02-09 다운그레이드 SVB Leerink Mkt Perform → Underperform
2022-01-18 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2021-11-19 개시 BMO Capital Markets Market Perform
2021-07-20 업그레이드 The Benchmark Company Hold → Buy
2021-02-10 다운그레이드 SVB Leerink Mkt Perform → Underperform
2021-01-07 개시 Truist Buy
2021-01-04 업그레이드 Guggenheim Neutral → Buy
2020-06-16 개시 The Benchmark Company Hold
2020-05-06 다운그레이드 JP Morgan Overweight → Neutral
2020-04-29 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2020-04-01 업그레이드 Morgan Stanley Equal-Weight → Overweight
2020-03-24 재개 William Blair Outperform
2020-03-13 업그레이드 BofA/Merrill Neutral → Buy
2020-02-04 재개 BofA/Merrill Neutral
2020-01-03 재확인 BMO Capital Markets Market Perform
2020-01-03 다운그레이드 Mizuho Buy → Neutral
2020-01-02 다운그레이드 Guggenheim Buy → Neutral
2019-10-03 개시 Mizuho Buy
2019-09-12 개시 BMO Capital Markets Market Perform
2019-09-05 업그레이드 JMP Securities Mkt Perform → Mkt Outperform
2019-09-05 재개 Morgan Stanley Equal-Weight
2019-09-05 업그레이드 Oppenheimer Perform → Outperform
2019-05-21 개시 Credit Suisse Neutral
2019-05-03 다운그레이드 Barclays Overweight → Equal Weight
2019-04-11 개시 Stifel Hold
2019-04-03 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2019-01-24 업그레이드 William Blair Mkt Perform → Outperform
모두보기

인사이트 코퍼레이션 주식(INCY)의 최신 뉴스

pulisher
May 09, 2025

New Incyte Suit Targets Broader Apotex Bid to Sell Jakafi Rival - Bloomberg Law News

May 09, 2025
pulisher
May 09, 2025

Sun shines on Leqselvi at Federal Circuit - BioWorld MedTech

May 09, 2025
pulisher
May 09, 2025

Merus annonce ses résultats financiers pour le premier trimestre 2025 et fait le point sur ses activités - GlobeNewswire Inc.

May 09, 2025
pulisher
May 08, 2025

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7, 2025 - BioSpace

May 08, 2025
pulisher
May 07, 2025

Fed. Circ. Clears Way For Sun Pharma Alopecia Drug - Law360

May 07, 2025
pulisher
May 07, 2025

US panel, finding no irreparable harm, vacates injunction against Sun Pharma - MLex

May 07, 2025
pulisher
May 07, 2025

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | INCY Stock News - GuruFocus

May 07, 2025
pulisher
May 07, 2025

Incyte Can’t Keep Sun’s Hair Drug Off Market, Appeals Court Says - Bloomberg Law News

May 07, 2025
pulisher
May 07, 2025

Incyte Reports Strong Q1 2025 Financial Results and Pipeline Progress - MyChesCo

May 07, 2025
pulisher
May 05, 2025

Chronic Hand Eczema Pipeline 2025: FDA Approvals, Therapies, - openPR.com

May 05, 2025
pulisher
May 05, 2025

Novartis, Incyte Settle Drug Royalty Fight On Eve Of Trial - Law360

May 05, 2025
pulisher
May 02, 2025

Incyte expects minimal tariff hit, lifts blood cancer drug's 2025 forecast - MSN

May 02, 2025
pulisher
May 01, 2025

Polycythemia vera Market: Epidemiology, Therapies, - openPR.com

May 01, 2025
pulisher
May 01, 2025

Alopecia Areata Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte Corp - Barchart.com

May 01, 2025
pulisher
May 01, 2025

Incyte to Present at Upcoming Investor Conference - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

Incyte (INCY) Target Price Raised Following Strong Q1 Performanc - GuruFocus

May 01, 2025
pulisher
Apr 30, 2025

9 Analysts Have This To Say About IncyteIncyte (NASDAQ:INCY) - Benzinga

Apr 30, 2025
pulisher
Apr 30, 2025

Incyte (INCY) Target Price Raised Following Strong Q1 Performance | INCY Stock News - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Incyte (INCY) Receives Adjusted Price Target from TD Cowen | INC - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

BofA Boosts Incyte (INCY) Price Target Following Q1 Results | IN - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Incyte (INCY) Target Price Raised by Wells Fargo Despite Mixed R - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Steroid Refactory Acute Graft-Versus-Host Disease Market Growth Projections 2023-2032: DelveInsight Analysis | MaaT Pharma, Medac GmbH, AltruBio Inc., Incyte Corporation - Barchart.com

Apr 30, 2025
pulisher
Apr 30, 2025

Incyte Corporation (NASDAQ:INCY) Q1 2025 Earnings Call Transcript - Insider Monkey

Apr 30, 2025
pulisher
Apr 30, 2025

Incyte: Q1 Earnings Snapshot - CT Insider

Apr 30, 2025
pulisher
Apr 30, 2025

Incyte Corp (INCY) Q1 2025 Earnings Call Highlights: Robust Reve - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

Incyte Corp (INCY) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... - Yahoo Finance

Apr 30, 2025
pulisher
Apr 30, 2025

Incyte to Showcase Latest Oncology Advancements at 2025 ASCO Meeting - MSN

Apr 30, 2025
pulisher
Apr 29, 2025

Earnings call transcript: Incyte Q1 2025 beats expectations, stock rises - Investing.com

Apr 29, 2025
pulisher
Apr 29, 2025

BofA raises Incyte stock price target to $89, maintains Buy rating - Investing.com

Apr 29, 2025
pulisher
Apr 29, 2025

Earnings call transcript: Incyte Q1 2025 beats expectations, stock rises By Investing.com - Investing.com Canada

Apr 29, 2025
pulisher
Apr 29, 2025

INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales - The Globe and Mail

Apr 29, 2025
pulisher
Apr 29, 2025

Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs - BioSpace

Apr 29, 2025
pulisher
Apr 29, 2025

Incyte Corp Raises Jakafi Sales Forecast Following Strong Performance - Finimize

Apr 29, 2025
pulisher
Apr 29, 2025

Incyte (INCY) Surpasses Q1 Revenue Expectations, Driven by Key P - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Incyte Corp reports results for the quarter ended March 31Earnings Summary - TradingView

Apr 29, 2025
pulisher
Apr 29, 2025

Incyte Q1 2025 slides: 26% product revenue growth, Jakafi guidance raised - Investing.com

Apr 29, 2025
pulisher
Apr 29, 2025

Incyte Corp (INCY) Q1 2025 Earnings: EPS of $0.80 Beats Estimate, Revenue Surges to $1.053 Billion - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs | INCY Stock News - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Incyte Q1 Results Top Estimates - Nasdaq

Apr 29, 2025
pulisher
Apr 29, 2025

Incyte (INCY) Surpasses Q1 Revenue Expectations, Driven by Key Products | INCY Stock News - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Incyte earnings beat by $0.12, revenue topped estimates - Investing.com

Apr 29, 2025
pulisher
Apr 29, 2025

Incyte (NASDAQ:INCY) Delivers Strong Q1 Numbers - Barchart.com

Apr 29, 2025
pulisher
Apr 29, 2025

Incyte Reports 2025 First Quarter Financial Results - TradingView

Apr 29, 2025
pulisher
Apr 29, 2025

Incyte (INCY) Set to Announce Q1 Earnings, Analysts Cautious - GuruFocus

Apr 29, 2025

인사이트 코퍼레이션 (INCY) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$65.08
price down icon 0.84%
$19.36
price down icon 0.31%
$33.15
price up icon 0.15%
$23.96
price down icon 2.80%
$92.77
price down icon 2.12%
biotechnology ONC
$231.99
price down icon 1.67%
자본화:     |  볼륨(24시간):